Veradermics MANE Research and development expenses paid with convertible and promissory notes
Research and development expenses paid with convertible and promissory notes at other companies
Other financials
Where this comes from
Reported directly by Veradermics in its filing.
Tagged under the XBRL concept mane:ResearchAndDevelopmentExpenseNoncashInExchangeForConvertibleNotes.
The official record: Veradermics ’s 10-K, filed March 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Veradermics 's research and development expenses paid with convertible and promissory notes.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Veradermics 's research and development expenses paid with convertible and promissory notes?
- Veradermics (MANE) reported research and development expenses paid with convertible and promissory notes of $0 in Q4 2025.
- How has Veradermics 's research and development expenses paid with convertible and promissory notes changed year-over-year?
- Veradermics 's research and development expenses paid with convertible and promissory notes decreased by 100.0% year-over-year, from $58.5K to $0.
- What does research and development expenses paid with convertible and promissory notes mean?
- R&D expenses paid using debt or convertible instruments instead of cash.
- How do you interpret research and development expenses paid with convertible and promissory notes?
- An increase suggests the company is conserving cash by leveraging debt, which may impact future capital structure.
- How does research and development expenses paid with convertible and promissory notes compare across companies?
- Frequently seen in early-stage biopharma companies managing cash burn.